Arrowstreet Capital
VPHM

Arrowstreet Capital’s VIROPHARMA INC VPHM Stock Holding History

Arrowstreet Capital’s Portfolio VPHM Stock Details VPHM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-155,535
Closed -$6.11M – 1416
2013
Q3 		$6.11M Buy
+155,535
New +$5.09M 0.04% 345

Other funds holding VPHM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Arrowstreet Capital's VPHM Position: Q4 2013 in Review

Arrowstreet Capital sold out of VIROPHARMA INC (VPHM) in Q4 2013, closing a stake of 155,535 shares — an estimated $6.11M sold.

Arrowstreet Capital first reported a position in VPHM in Q3 2013 and held it in 1 quarter. The position peaked at $6.11M in Q3 2013. 172 funds tracked by Wall St. Rank hold VPHM as of Q4 2013.

  • Arrowstreet Capital reported no remaining VIROPHARMA INC position as of Q4 2013 after selling out during the quarter.
  • Arrowstreet Capital sold 155,535 VIROPHARMA INC shares in Q4 2013, an estimated $6.11M.
  • Arrowstreet Capital first reported a position in VIROPHARMA INC in Q3 2013 and held it in 1 quarter.
  • Arrowstreet Capital's VIROPHARMA INC position peaked at $6.11M in Q3 2013.
  • 172 funds tracked by Wall St. Rank held VIROPHARMA INC as of Q4 2013.

Based on Arrowstreet Capital's 13F filing for Q4 2013, filed 14 Feb 2014.